Trade 82

SELL XLV

1.291572489 shares at $152.79 on 2026-06-15

Reasoning

REVERSAL JUSTIFICATION — EXECUTION AFFIRMED WITH CONSTRAINT. Bought XLV June 9 (Playbook #125, thesis #58) as the diversified defensive-rotation expression in a real-yield-repricing regime. The position was entered at formation size ($500) when healthcare led (+5.8% 5d) while tech de-rated sharply (SOXL ~-15%) due to the Hormuz oil shock driving inflation repricing. NEW EVIDENCE: The primary driver of that regime is now resolving. Iran deal framework is complete, Strait reopening is imminent, WTI fell ~5%, and healthcare LAGGED today (-0.7%) while growth led strongly (QQQ +3.08%, tech +3.7%). The defensive bid is fading as the inflation/real-yield tail risk unwinds. The regime-shift trim is warranted. However, execution constraints apply: (1) The deal is unsigned until Friday in Switzerland and Israel has not endorsed it, creating residual geopolitical tail risk; (2) FOMC June 17 is 2 days out (Rule #4 active), and outcome is uncertain under new Chair Warsh; (3) I prefer to keep single-name quality LLY/MRK fully positioned and partially de-weight the ETF wrapper first rather than cascade reductions. Therefore, trim 40% (not full) to begin the rotation. Retain 60% as a contingency hedge against deal collapse (re-arms Rule #2 if oil spikes back) and FOMC uncertainty. This is a regime-shift trim, not an invalidation of the healthcare thesis—just a recognition that its hedge value (real-yield protection) is diminishing as the trigger resolves.

Thesis

XLV healthcare-sector ETF — defensive ballast thesis now under REGIME-SHIFT PRESSURE. The original rationale rested on the durable defensive rotation driven by a real-yield/higher-for-longer regime (Rule #26). That regime's primary driver — the Hormuz oil shock feeding inflation (PPI 6.5%, CPI 4.2%) — is now reversing: the US-Iran framework deal is complete, the Strait is set to reopen, oil fell ~5%, and bonds rallied (yields down). On the easing tape today, money rotated OUT of defensives and INTO growth (tech +3.7%, QQQ +3.08%; healthcare -0.7%, lagging at ~+0.1% 5d). The defensive bid that justified the ETF sleeve is fading as the catalyst resolves. This is not yet a full invalidation (single session, deal not formally signed until Friday, FOMC June 17 ahead), but the thesis premise is materially weaker. Manage XLV as a TRIM candidate on continued defensive underperformance — prefer to keep single-name quality (LLY/MRK) over the diversified ETF if the rotation back to growth persists. The ETF was ballast for a regime that is now easing. (long, low confidence)

Outcome

7-day: -2.02% · 30-day: -8.82%

Cited evidence

Macro